{"schema_version":"1.0","type":"article","title":"台灣這家Biotech將吃下AI基礎建設的所有紅利？","url":"https://drugnews.com.tw/articles/2026-04-18-biotech-ai.html","markdown_url":"https://drugnews.com.tw/articles/2026-04-18-biotech-ai.md","lang":"zh-Hant","date":"2026-04-18","publish_at":"2026-04-18T10:30:00+08:00","updated_at":"2026-04-18","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","AI","自體免疫","臨床數據","生技投資"],"summary":"AI 吃電，核電回來了：為什麼麗寶新藥，可能站在下一個被重估的位置？","key_points":[],"facts":[],"sections":[],"references":[{"title":"公開資料＆各公司官網","source":"","date":"","url":""},{"title":"![Dcard 原圖：台灣這家Biotech將吃下AI基礎建設的所有紅利？（圖 3）](images/dcard-03.png","source":"","date":"","url":""},{"title":"![Dcard 原圖：台灣這家Biotech將吃下AI基礎建設的所有紅利？（圖 4）](images/dcard-04.png","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：台灣這家Biotech將吃下AI基礎建設的所有紅利？（圖 1）","url":"https://drugnews.com.tw/assets/articles/biotech-ai/dcard-01.webp"},{"alt":"Dcard 原圖：台灣這家Biotech將吃下AI基礎建設的所有紅利？（圖 2）","url":"https://drugnews.com.tw/assets/articles/biotech-ai/dcard-02.png"},{"alt":"Dcard 原圖：台灣這家Biotech將吃下AI基礎建設的所有紅利？（圖 3）","url":"https://drugnews.com.tw/assets/articles/biotech-ai/dcard-03.png"},{"alt":"Dcard 原圖：台灣這家Biotech將吃下AI基礎建設的所有紅利？（圖 4）","url":"https://drugnews.com.tw/assets/articles/biotech-ai/dcard-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/biotech-ai/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-04-18）。台灣這家Biotech將吃下AI基礎建設的所有紅利？。https://drugnews.com.tw/articles/2026-04-18-biotech-ai.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-04-18-biotech-ai-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}